Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药
。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药
。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药物。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓一种选择性雌激素受体调节剂,为预防绝经
骨质疏松症药物。
声明:以上例句、词性分类均网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药物。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其容亦不代
本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择素受体调节剂,为预防绝经
骨质疏松症药物。
声明:以上、词
分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药物。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其容亦不代
本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症
物。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
卓昔芬是一种选择性雌激素受体调节剂,为预防绝经
骨质疏松症药物。
声明:以上例、词性分类均由互联网
动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经骨质疏松症药物。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,内容亦不代
本软件的观点;若发现问题,欢迎向我们指正。